SCHEMBL7583531

SCHEMBL7583531

c1cnc2nc(C3CCCCC3)[nH]c2c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 1/20 0.54
PDE5A O76074 1/20 0.49
PDE4A P27815 1/20 0.49
PDE4B Q07343 1/20 0.49
PDE4C Q08493 1/20 0.49
PDE4D Q08499 1/20 0.49
NUDT1 P36639 1/20 0.49
SMO Q99835 1/20 0.47
AURKA O14965 2/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
MAPT P10636 2/20 0.46
KDM4E B2RXH2 1/20 0.46
GFER P55789 1/20 0.46
ADORA3 P0DMS8 2/20 0.45
ADORA2A P29274 2/20 0.45
ADORA1 P30542 2/20 0.45
ADORA2B P29275 1/20 0.45
METAP2 P50579 1/20 0.44
METAP1 P53582 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4048712 0.95 NPY5R (0.55) NPY5RPDE5APDE4APDE4BPDE4C
SCHEMBL4111938 0.92 NPY5R (0.57) NPY5RPDE5APDE4APDE4BPDE4C
SCHEMBL14447540 0.86 NPY5R (0.53) NPY5RPDE5APDE4APDE4BPDE4C
SCHEMBL20284753 0.84 PARP1 (0.56) NPY5RNUDT1AURKA
SCHEMBL5016405 0.78 AKT1 (0.61) NPY5RSMOALDH1A1
SCHEMBL724921 0.75 NPC1 (0.62) NPY5RNPC1RAB9AMAPTKDM4E
SCHEMBL6757201 0.75 NPC1 (0.62) NPY5RNPC1RAB9AMAPTKDM4E
SCHEMBL10600439 0.74 NPC1 (0.43) NPC1RAB9AMAPTKDM4EGFER
SCHEMBL4062469 0.74 USP30 (0.63) ADORA3ADORA2AADORA1ADORA2B
SCHEMBL6756134 0.73 NPC1 (0.59) NPY5RNPC1RAB9AMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6495561-B2 TREATING MIGRAINE, DEPRESSION, ANXIETY, SCHIZOPHRENIA, PARKINSON'S DISEASE, OR STROKE MERCK & CO., INC. 2002-12-17 US disclosed
US-20020055519-A1 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists MERCK SHARP & DOHME CORP. 2002-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020055519-A1 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists GRIN2C, GRIN1, GRIN3A NPY5R 1436/4885PDE5A 4469/4885PDE4A 3244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.